MGC Pharmaceuticals Limited (MXC.L) Research

MGC Pharmaceuticals Limited, a biopharmaceutical firm, is engaged in the creation and provision of plant-derived medicines across Australia, Israel, and Slovenia. Its primary product pipeline features CimetrA, currently undergoing Phase III clinical trials for the treatment of early-stage COVID-19. Also in development is CannEpil, a Phase IIb cannabis-derived treatment designed for epilepsy that is resistant to other drugs, and CogniCann, which is in Phase II clinical trials for alleviating dementia symptoms. The company maintains research and development partnerships with the Royal Melbourne Institute of Technology and the University of Notre Dame. Furthermore, it collaborates with the Slovenian National Institute of Biology and the Neurosurgery Department at the University Medical Centre. Originally known as Erin Resources Limited, the company adopted its current name, MGC Pharmaceuticals Limited, in December 2015. Established in 2014, its main office is located in West Perth, Australia.

Open MGC Pharmaceuticals Limited (MXC.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.